Brainstorm Cell Therapeutics Inc. (BCLI)
NASDAQ: BCLI · Real-Time Price · USD
1.800
-0.060 (-3.23%)
Nov 4, 2024, 4:00 PM EST - Market closed
BCLI Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Net Income | -12.75 | -17.19 | -24.28 | -24.46 | -31.81 | -23.25 | |
| Depreciation & Amortization | 0.26 | 0.27 | 0.29 | 0.26 | 0.22 | 0.16 | |
| Stock-Based Compensation | 0.86 | 1.49 | 1.68 | 1.37 | 2.56 | 0.79 | |
| Change in Accounts Receivable | 0.12 | -0.48 | 1.07 | 0.34 | 1.49 | 0.69 | |
| Change in Accounts Payable | 0.15 | -1.27 | 2.52 | -1.72 | -9.26 | 10.13 | |
| Change in Other Net Operating Assets | -3.09 | -3.28 | -0.6 | -2.05 | 1.61 | 0.23 | |
| Operating Cash Flow | -14.44 | -20.46 | -19.32 | -26.27 | -35.19 | -11.25 | |
| Capital Expenditures | -0.02 | -0.02 | -0.03 | -0.33 | -0.38 | -0.47 | |
| Investment in Securities | 0.2 | 2.21 | 1.03 | 0.65 | -4.07 | 6.09 | |
| Investing Cash Flow | 0.18 | 2.19 | 1 | 0.32 | -4.45 | 5.62 | |
| Issuance of Common Stock | 17.36 | 18.98 | 0.24 | 6.97 | 77.05 | 5.23 | |
| Repurchase of Common Stock | - | - | - | - | -0.12 | - | |
| Financing Cash Flow | 17.36 | 18.98 | 0.24 | 6.97 | 76.94 | 5.23 | |
| Net Cash Flow | 3.1 | 0.71 | -18.08 | -18.97 | 37.29 | -0.41 | |
| Free Cash Flow | -14.46 | -20.48 | -19.35 | -26.6 | -35.57 | -11.72 | |
| Free Cash Flow Per Share | -3.74 | -7.13 | -7.95 | -11.03 | -17.88 | -8.03 | |
| Levered Free Cash Flow | -8.45 | -12.49 | -10 | -17.64 | -23.81 | -3.46 | |
| Unlevered Free Cash Flow | -8.18 | -12.31 | -10 | -17.64 | -23.73 | -3.3 | |
| Change in Net Working Capital | -0.91 | 0.65 | -3.58 | 3.6 | 6.33 | -10.59 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.